BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

3DM Inc. Launches PuraMatrix Through Partnership With BD Biosciences (BDX)


10/19/2005 5:11:55 PM

CAMBRIDGE, Mass., Oct. 26 /PRNewswire/ -- 3DM, Inc., a Cambridge-based developer of synthetic biomaterial polymers, has announced a worldwide co- branded marketing and distribution partnership with BD Biosciences - Discovery Labware. The limited-exclusive partnership supplies BD Biosciences with 3DM's award-winning PuraMatrix Synthetic Peptide Hydrogel. The product line will be marketed by BD Biosciences as BD(TM) PuraMatrix(TM) Peptide Hydrogel.

"We are very excited to launch BD(TM) PuraMatrix(TM) Peptide Hydrogel, the latest addition to our extensive product line for 3D cell culture, drug discovery, tissue engineering, and stem cell biology," said David Freeman, VP, Marketing, BD Biosciences - Discovery Labware. "It is a truly novel technology with a myriad of applications in the life sciences. We are extremely encouraged by the publication of numerous studies from distinguished research institutions that are currently using this important biomaterial."

BD Biosciences will market these products to the drug discovery and life science research communities as a novel nanobiotechnology for the culture of cells and tissues. Applications include cell-based assays, tissue engineering, cell biology research, and stem cell bioproduction.

"This partnership with BD Biosciences is a major milestone in our mission to enable broad use of PuraMatrix across multiple life science and drug discovery applications," said Zen Chu, President and co-founder of 3DM. "This relationship serves as a foundation to advance new PuraMatrix applications, including toxicology testing models, cancer biology, tissue models for drug discovery, and stem cell regenerative medicine."

About PuraMatrix

PuraMatrix Hydrogels are used to create synthetic nanofiber scaffolds to culture cells for basic research, drug discovery and bioproduction. Clinical versions of PuraMatrix are currently in animal testing for medical device applications in orthopedic implants and cardiac regeneration.

  PuraMatrix provides a number of advantages over current solutions:
  * Synthetic and transparent yet biocompatible hydrogel composition (1%
    peptide [w/v] 99% water)
  * Cultures and supports attachment of most cell and tissue types in highly
    defined conditions
  * Supports hepatotoxicity, angiogenesis, stem cell proliferation and tumor
    cell motility assays
  * Promotes differentiation of hepatocyte progenitor cells and other cell
    types

BD(TM) PuraMatrix(TM) is distributed exclusively through BD Biosciences. Product information can be found at: http://www.bdbiosciences.com/discovery_labware/Products/tissue_engineering/PuraMatrix

PuraMatrix(TM) is forward compatible with in vivo implant studies and bioproduction requirements, and is already in use at major pharmaceutical companies and clinical research institutions. Other versions of PuraMatrix are compatible with cGMP quality requirements and clinical therapeutics and are available directly from 3DM Inc.

About 3DM, Inc.

3DM is a privately-held specialty biomaterials and medical device company headquartered in Cambridge, Mass. The patented technology, exclusively licensed from Massachusetts Institute of Technology, was pioneered through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert Langer, Alexander Rich, Carlos Semino and Lisa Spirio. Contact 3DM directly for supplying high volume and GMP-quality applications for bioproduction, medical devices and drug delivery applications at http://www.puramatrix.com/.

Contact: Zen Chu, President 3DM, Inc. 877-430-9595 contact@puramatrix.com Media: Jennifer Gray MacDougall BioCommunications 508-647-0209

3DM, Inc.

CONTACT: Zen Chu, President of 3DM, Inc., +1-877-430-9595,contact@puramatrix.com; or Jennifer Gray of MacDougall BioCommunications,+1-508-647-0209



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES